Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial
Go back to Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 182.56 +9.62 (5.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $172.94 | 52 Week High | $0.52 | |||
| Open | $168.50 | 52 Week Low | $0.08 | |||
| Day High | $187.20 | P/E | N/A | |||
| Day Low | $168.30 | EPS | $-3.80 | |||
| Volume | 24,025,037 | |||||
